Last updated: September 8, 2026
Gadodiamide is a mature, off-patent gadolinium-based contrast agent marketed primarily under the Omniscan brand. Its commercial position has deteriorated because of nephrogenic systemic fibrosis risk, gadolinium retention concerns, regulatory restrictions, and substitution by newer macrocyclic agents. No reliable public source reports standalone gadodiamide revenue. Current value is concentrated in legacy supply, hospital formulary contracts, and residual use in markets where price remains the primary purchasing criterion.
What is gadodiamide and how is it used?
Gadodiamide is a nonionic, linear gadolinium-based contrast agent used with magnetic resonance imaging. The original branded product is Omniscan, historically associated with GE Healthcare and its predecessor Amersham businesses.
Gadodiamide has been used for contrast-enhanced MRI of the central nervous system, including brain and spine imaging, and for other approved MRI applications depending on jurisdiction and labeling.
| Attribute |
Gadodiamide profile |
| Active ingredient |
Gadodiamide |
| Brand |
Omniscan |
| Drug class |
Gadolinium-based contrast agent |
| Molecular structure |
Linear, nonionic chelate |
| Original sponsor |
Sanofi/Amersham lineage; later GE Healthcare |
| U.S. regulatory pathway |
New Drug Application |
| Primary clinical use |
Contrast-enhanced MRI |
| Current commercial position |
Mature, heavily substituted product |
| Biosimilar status |
Not applicable |
| Main competitors |
Gadobutrol, gadoterate meglumine, gadoteridol, gadobenate dimeglumine |
The product’s commercial decline reflects clinical risk differentiation rather than loss of imaging utility. Gadodiamide remains an effective MRI contrast agent, but it is classified among the higher-risk linear agents for nephrogenic systemic fibrosis in patients with severe renal impairment.
When did gadodiamide lose exclusivity?
Gadodiamide lost meaningful market exclusivity years ago. The original composition, formulation, and manufacturing patent estate was based on technology developed in the 1980s and early 1990s. The core patent term would have expired by the 2000s, leaving no durable patent barrier to generic or alternative contrast-agent competition.
The product’s commercial exclusivity timeline is best understood as follows:
| Period |
Commercial event |
Market effect |
| Early 1990s |
U.S. approval and launch of Omniscan |
Establishes gadodiamide in MRI contrast |
| Late 1990s to early 2000s |
Expansion of MRI utilization |
Supports volume growth |
| 2000s |
Core patents expire and competing GBCAs expand |
Reduces exclusivity |
| 2006 onward |
Nephrogenic systemic fibrosis reports and regulatory warnings |
Weakens use in renal-risk patients |
| 2010 onward |
European restrictions on several linear agents |
Accelerates substitution |
| 2017 onward |
FDA class labeling and gadolinium-retention communications |
Increases institutional scrutiny |
| 2020s |
Macrocyclic agents gain preference |
Pushes gadodiamide toward legacy use |
The Orange Book does not provide a meaningful current exclusivity story for gadodiamide. Any historical listed patents associated with the original NDA have either expired or ceased to provide commercially significant protection. The relevant competitive question is no longer whether a competitor can enter under patent law. It is whether the competitor can secure supply, regulatory approval, hospital access, and acceptable clinical positioning.
What is the FDA regulatory status of gadodiamide?
Gadodiamide remains an FDA-recognized MRI contrast agent, but its labeling carries important renal-risk restrictions. FDA classifies gadodiamide among Group I GBCAs associated with the greatest number of reported nephrogenic systemic fibrosis cases.
FDA communications require class-level warnings for gadolinium-based contrast agents and emphasize screening of patients at risk for renal dysfunction. FDA has also required medication-guide and labeling changes addressing gadolinium retention in the body. FDA stated that the clinical consequences of gadolinium retention had not been established, while retaining restrictions for patients at risk of nephrogenic systemic fibrosis (FDA, 2017; FDA, 2018).
The regulatory status differs materially by region:
| Jurisdiction |
Status and commercial implication |
| United States |
Approved product category with strong renal-risk warnings |
| European Union |
Linear-agent restrictions and suspensions materially reduced use |
| Japan and other Asian markets |
Availability and labeling depend on national regulators |
| Hospitals and imaging networks |
Formulary decisions often favor macrocyclic alternatives |
In Europe, the European Medicines Agency restricted or suspended several linear GBCAs because of gadolinium retention and nephrogenic systemic fibrosis concerns. The European action had a greater commercial effect on gadodiamide than ordinary generic competition because it reduced institutional willingness to use the product.
What patents protect gadodiamide?
No active patent estate is likely to protect gadodiamide as a commercial product in the United States. The main protection periods associated with the original gadodiamide technology have expired.
Potential historical protection categories included:
- The gadodiamide chelate and related complexing chemistry.
- Pharmaceutical compositions containing gadodiamide.
- Injectable formulations and stabilizers.
- Manufacturing methods for preparing the gadolinium complex.
- MRI contrast methods using gadodiamide.
These categories do not create a material present-day barrier. Any residual patent claims would need to cover a narrow manufacturing process, specific formulation, device, or method of use. Such claims would not restore broad product exclusivity.
How strong is the gadodiamide patent estate?
The patent estate is commercially weak for four reasons:
- The original product is more than two decades past launch.
- Core composition patents have expired.
- Gadolinium contrast agents can be substituted without infringing gadodiamide-specific claims.
- Current demand is constrained by safety preferences rather than patent access.
The principal risk to a generic manufacturer is therefore regulatory and commercial. A supplier must demonstrate injectable quality, sterility, stability, reliable gadolinium content, and uninterrupted manufacturing capacity. These requirements create operational barriers but do not support premium pricing.
Are there Paragraph IV challenges or generic competitors?
Gadodiamide is not a major current Paragraph IV litigation market. The product’s commercial decline and old patent estate reduce the incentive to pursue an aggressive patent challenge.
Public FDA materials do not indicate a large, active generic ecosystem comparable to older small-molecule tablets. Injectable contrast agents have more complex manufacturing, packaging, quality-control, and supply-chain requirements than conventional oral generics. The absence of a large generic field does not indicate patent protection. It reflects limited expected returns and strong competition from established contrast-agent manufacturers.
Potential suppliers include manufacturers with experience in sterile injectables and radiology products. Competition is more likely to occur through hospital contracting, tender pricing, and portfolio sales than through a branded-versus-generic patent battle.
What formulations are protected by gadodiamide patents?
The commercially relevant formulation is an injectable aqueous solution administered intravenously. Historical formulation protection may have covered concentration, pH, stabilizers, excipients, or manufacturing parameters.
No formulation category appears capable of sustaining current market exclusivity. The formulation is relatively conventional compared with depot injections, antibody-drug conjugates, inhaled systems, or complex drug-device products. A manufacturer with suitable sterile injectable capability can generally compete through an approved equivalent or a jurisdiction-specific product.
The more relevant technical barriers are:
- Sterile manufacturing.
- Control of elemental impurities.
- Chelate purity and stability.
- Prevention of particulate contamination.
- Container-closure integrity.
- Consistent MRI relaxivity and dose performance.
- Validated supply of gadolinium-containing raw materials.
What patent litigation affects gadodiamide?
Gadodiamide has been implicated in broader litigation concerning gadolinium-based contrast agents and alleged injuries associated with gadolinium retention, nephrogenic systemic fibrosis, and other claimed effects.
The most important U.S. proceeding was multidistrict litigation involving gadolinium-based contrast agents, including products marketed by GE Healthcare and other manufacturers. The litigation created liability exposure for manufacturers and increased the reputational and contracting costs associated with older linear agents.
The litigation risk is distinct from patent risk. Product-liability cases generally concern warnings, causation, injury, and regulatory compliance. They do not extend gadodiamide exclusivity or prevent generic competition.
Current commercial diligence should distinguish:
- Historical multidistrict litigation.
- Individual product-liability claims.
- Regulatory warning changes.
- Any settlement agreements or confidential resolutions.
- Insurance and indemnification arrangements connected with legacy products.
Publicly disclosed settlement economics are not sufficiently granular to attribute a reliable cumulative financial charge specifically to gadodiamide.
How does gadodiamide compare with newer MRI contrast agents?
Gadodiamide competes primarily with macrocyclic GBCAs. Macrocyclic agents hold the gadolinium ion more tightly than linear agents and are generally preferred where institutions seek to minimize retention and renal-risk concerns.
| Product |
Structure |
Commercial position |
| Gadodiamide |
Linear, nonionic |
Legacy product; weaker safety positioning |
| Gadobutrol |
Macrocyclic, nonionic |
Strong global hospital presence |
| Gadoterate meglumine |
Macrocyclic, ionic |
Frequently preferred for safety positioning |
| Gadoteridol |
Macrocyclic, nonionic |
Established premium competitor |
| Gadobenate dimeglumine |
Linear, ionic |
Specialized and regionally variable |
Macrocyclic products have benefited from institutional protocols that prioritize lower retention concerns. Their pricing may be higher, but hospitals often evaluate contrast agents on total imaging workflow, safety policy, supply reliability, and litigation exposure rather than vial price alone.
What is the financial trajectory of gadodiamide?
Gadodiamide’s financial trajectory is a long-term decline from an established branded MRI product to a low-growth or declining legacy product.
Standalone revenue is not publicly disclosed in the financial reporting of GE HealthCare or its predecessor companies. Gadodiamide is included, if at all, within broader pharmaceutical diagnostics or contrast-media revenue. GE HealthCare reports segment-level performance rather than product-level sales for Omniscan.
Revenue trajectory
| Financial phase |
Revenue condition |
Main driver |
| Launch and adoption |
Growth |
Expansion of MRI capacity and branded uptake |
| Mature brand period |
High but slowing |
Installed MRI base and physician familiarity |
| Post-patent period |
Decline |
Generic pressure and therapeutic alternatives |
| Safety-restriction period |
Accelerated decline |
NSF concerns and regulatory restrictions |
| Current period |
Low and residual |
Legacy contracts, price-sensitive markets, limited use |
The product’s revenue exposure to GE HealthCare is likely immaterial relative to the company’s total revenue and its broader Pharmaceutical Diagnostics portfolio. The company’s financial results are driven by a diversified set of X-ray, CT, MRI, ultrasound, molecular imaging, and contrast products. Omniscan therefore has limited ability to affect consolidated growth, margins, or valuation.
Margin outlook
A legacy contrast agent can remain cash-generative if manufacturing assets are fully depreciated and demand is stable. Gadodiamide’s margin profile is constrained by:
- Low pricing after loss of exclusivity.
- Quality requirements for sterile injectable products.
- Product-liability reserves and legal costs.
- Lower production volumes.
- Competition from larger contrast portfolios.
- Potential inventory and regulatory-compliance costs.
The product may generate positive contribution margin in selected markets, but it is unlikely to be a strategic growth asset.
What licensing deals involve gadodiamide?
No major recent licensing transaction centered specifically on gadodiamide is publicly established. The product’s commercial history is linked more closely to corporate acquisitions and portfolio ownership than to ongoing licensing economics.
The relevant ownership chain includes the transfer of Amersham’s pharmaceutical and imaging businesses into GE Healthcare. Current commercial decisions are more likely to involve manufacturing rights, regional distribution, contract supply, or portfolio tenders than a new global license for gadodiamide.
A licensing transaction would face limited upside because:
- Core patents are expired.
- Clinical preference has shifted toward macrocyclic agents.
- Regulatory restrictions narrow the addressable market.
- Buyers can obtain alternative GBCAs from established suppliers.
- Product-liability diligence would be material.
What generic launch risks exist for gadodiamide?
A generic launch would face low patent risk but moderate execution risk.
Regulatory risks
The sponsor would need to address renal-risk labeling, contraindications or warnings, pharmacovigilance, and jurisdiction-specific restrictions. European approval would be particularly challenging from a commercial perspective because historical restrictions on linear agents reduce market access.
Manufacturing risks
The product requires validated sterile production and dependable supply of high-purity gadolinium chelate components. Any quality failure could result in hospital delisting or regulatory action.
Commercial risks
Hospitals may prefer macrocyclic agents even when gadodiamide is cheaper. Imaging centers often purchase contrast agents through bundled contracts, limiting the ability of a single-product entrant to win share.
Litigation risks
A new entrant would inherit product-liability exposure associated with warnings, patient injury allegations, and historical gadolinium litigation. This risk may deter smaller manufacturers.
What is the competitive outlook for gadodiamide?
The competitive outlook is defensive. Gadodiamide is unlikely to regain meaningful share in the United States or Europe unless severe supply constraints affect alternative GBCAs.
The strongest remaining market opportunities are:
- Price-sensitive public tenders.
- Markets with continued use of linear GBCAs.
- Facilities with existing Omniscan protocols.
- Regions where macrocyclic supply is limited.
- Contract manufacturing or portfolio-based sales.
The largest downside risks are further formulary restrictions, discontinuation by the originator, stricter national warnings, and substitution by gadobutrol, gadoterate, or gadoteridol.
Key Takeaways
- Gadodiamide is a mature, off-patent MRI contrast agent marketed historically as Omniscan.
- Its commercial decline is driven primarily by safety positioning and substitution, not patent expiration alone.
- The product belongs to the higher-risk Group I GBCA category for nephrogenic systemic fibrosis.
- Macrocyclic agents have gained preference because of lower perceived gadolinium-retention and renal-risk concerns.
- No meaningful current patent barrier appears to protect gadodiamide.
- Paragraph IV litigation is not the principal competitive issue.
- Standalone revenue is not publicly disclosed and is embedded within broader contrast-media reporting.
- Current financial value is likely limited to residual supply, legacy contracts, and selected price-sensitive markets.
- The product is not a biosimilar opportunity because gadodiamide is a conventional small-molecule contrast agent.
- Generic entry risk is commercially moderate but patent risk is low.
FAQs about gadodiamide
Is gadodiamide still available in the United States?
Gadodiamide remains an FDA-recognized MRI contrast agent, but use is constrained by renal-risk warnings, safety preferences, and competition from macrocyclic GBCAs.
Is Omniscan the same as gadodiamide?
Yes. Omniscan is the principal historical brand associated with gadodiamide.
Does gadodiamide have an active U.S. patent?
No material broad patent exclusivity is expected to remain. The original composition and core product patents have expired.
Why did hospitals move away from gadodiamide?
Hospitals shifted toward macrocyclic agents because of concerns involving nephrogenic systemic fibrosis, gadolinium retention, regulatory restrictions, and product-liability exposure.
Is gadodiamide a biosimilar?
No. Gadodiamide is a small-molecule gadolinium contrast agent. Biosimilar pathways apply to biologic products, not conventional MRI contrast agents.
References
-
European Medicines Agency. (2017). EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans. https://www.ema.europa.eu/
-
European Medicines Agency. (2010). European Medicines Agency recommends suspending marketing authorisations for Omniscan, Optimark and Magnevist in patients with severe kidney problems. https://www.ema.europa.eu/
-
GE HealthCare Technologies Inc. (2024). Annual report for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2017). FDA warns that gadolinium-based contrast agents are retained in the body; requires new class warnings. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2018). Gadolinium-based contrast agents: Drug safety communication. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drug products. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
